Related references
Note: Only part of the references are listed.Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
Katherine A. Janeway et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
KIT as a Therapeutic Target in Melanoma
Maria C. Garrido et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes
Bernadette Liegl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors
Cristina R. Antonescu et al.
CANCER RESEARCH (2009)
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
Tianhua Guo et al.
CLINICAL CANCER RESEARCH (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Imatinib in the treatment of solid tumours
Florence Duffaud et al.
TARGETED ONCOLOGY (2009)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
Ronald P. DeMatteo et al.
CANCER (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1
Chiara Mussi et al.
CLINICAL CANCER RESEARCH (2008)
Molecular characterization of pediatric gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2008)
Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene
H-U Schildhaus et al.
JOURNAL OF PATHOLOGY (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
SGX393 inhibits the CML mutant Bcr-AblT3151 and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
Chi Tarn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
BRAFE600 in benign and malignant human tumours
C. Michaloglou et al.
ONCOGENE (2008)
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD
Barbara Pasini et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2008)
The prevalence and prognostic value of BRAF mutation in thyroid cancer
Electron Kebebew et al.
ANNALS OF SURGERY (2007)
Genetics of carney triad:: Recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors
Ludmila Matyakhina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor
Satoru Yuzawa et al.
CELL (2007)
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
Cristina R. Antonescu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis
P. Minoo et al.
JOURNAL OF PATHOLOGY (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Results of tyrosine-kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
Ronald P. DeMatteo et al.
ANNALS OF SURGERY (2007)
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2007)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F. R. Hirsch et al.
ANNALS OF ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response
Jae-Lyun Lee et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor
Ferdinand Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N. Boissel et al.
LEUKEMIA (2006)
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy
K Wyman et al.
CANCER (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients
O Maertens et al.
HUMAN MOLECULAR GENETICS (2006)
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate
J Cammenga et al.
BLOOD (2005)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall
P Pauwels et al.
HISTOPATHOLOGY (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel et al.
BRITISH JOURNAL OF CANCER (2005)
Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations -: A report of three cases
R Cairoli et al.
LEUKEMIA RESEARCH (2005)
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases - Implications for clinical resistance in targeted cancer treatment
N von Bubnoff et al.
CELL CYCLE (2005)
Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α (PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22)
M Hiwatari et al.
LEUKEMIA (2005)
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225
GA McArthur et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
M Debiec-Rychter et al.
GASTROENTEROLOGY (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential
J Lasota et al.
LABORATORY INVESTIGATION (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors
E Wardelmann et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment
N Sirvent et al.
GENES CHROMOSOMES & CANCER (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani et al.
BLOOD (2003)
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
RG Maki et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
